NASDAQ$LIVN

LivaNova PLC · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

LIVN Q1 2024 — £295K revenue, 31.00 EPS

As a result, the Company’s actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by th. LivaNova PLC reported Q1 2024 results. Diluted EPS came in at 31.00. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: £295K.
  • Diluted EPS: 31.00.
  • Gross profit: £207K.

Headline financials

Total Revenue

$295M

Previous: $263M+12.0%
EPS

-$0.78

Previous: $0.43-281.4%
Capital Expenditures

-$6.4M

Previous: -$7.69M+16.7%
Free Cash Flow

-$48.3M

Previous: -$315K-15246.3%
Net Income

-$41.9M

Previous: $7.37M-669.1%
Operating Income

$16.2M

Previous: -$2.34M+793.7%
Gross Profit

$207M

Previous: $174M+19.1%
Cash & Equivalents

$309M

Previous: $214M+44.3%
Total Assets

$2.46B

Previous: $2.29B+7.2%
R&D Expense

$44.9M

No prior period
Stock-Based Comp

$10.2M

Previous: $10.6M-3.3%

Revenue & EPS history

LivaNova · Revenue · Quarterly

$295M

Q1 2024+12%vs Q1 2023
Beat estimate in 14 of 15 quarters(93%)
ActualEstimate

Revenue by segment

LivaNova · $265M total across 3 segments · Q4 2022

  • Cardiopulmonary
    $137M
  • Neuromodulation
    $127M
  • Other Revenue
    $1.6M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+1.2%

Avg return

Earnings day

+0.9%

Avg return

5 days after

+1.3%

Avg return

30 days after

58%

26 / 45 earnings

Positive

+23.3%

Q1 2025

Best reaction

-19.9%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+15.1%+21.7%+25.5%
Q4 2025+0.8%+1.8%-10.4%
Q3 2025-5.8%-5.7%+17.5%
Q1 2025+23.3%+28.6%+30.7%
Q4 2024-15.8%-15.9%-20.0%
Q3 2024-2.5%-7.5%-0.9%
Q2 2024-5.8%-11.8%-1.8%
Q1 2024+12.9%+12.3%+9.5%
Q4 2023+6.9%+6.4%+6.4%
Q3 2023-0.8%-0.9%-6.4%
Q2 2023+7.0%+9.1%+4.0%
Q1 2023+0.6%-0.0%-0.6%
Q4 2022-9.6%-12.1%-23.6%
Q3 2022+2.2%+6.6%+19.1%
Q2 2022-3.0%-2.2%-13.9%
Q1 2022-13.2%-21.8%-9.1%
Q4 2021+7.9%+9.4%+8.6%
Q3 2021+15.3%+15.9%+2.4%
Q2 2021+8.0%+7.1%+1.1%
Q1 2021+3.8%+1.4%+0.8%
Q4 2020+3.5%+3.6%+2.6%
Q3 2020+1.0%-4.5%+8.9%
Q2 2020-11.0%-17.2%-14.9%
Q1 2020-5.8%-10.4%-5.1%
Q4 2019+3.3%+5.2%-34.6%
Q3 2019-6.8%-6.4%+10.4%
Q2 2019+5.8%+1.7%+2.5%
Q1 2019+5.2%+8.8%+4.4%
Q4 2018-4.2%-3.1%+0.0%
Q3 2018+5.6%+6.9%-6.6%
Q2 2018+12.2%+10.3%+14.0%
Q1 2018-8.0%-6.7%+5.9%
Q4 2017+2.4%+0.8%+1.1%
Q3 2017+11.7%+9.1%+20.3%
Q2 2017+1.4%+1.5%+7.7%
Q1 2017+4.0%+4.8%+7.0%
Q4 2016+4.2%-2.0%-2.8%
Q3 2016-19.9%-21.0%-19.3%
Q2 2016+14.9%+11.1%+12.0%
Q1 2016-3.5%
Q4 2014-0.0%
Q4 2013-0.0%
Q4 2015-1.1%
Q2 2015+1.9%
Q3 2015-10.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro